Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial.
Elisabetta PetracciEmanuela ScarpiAlessandro PassardiAnnibale BiggeriCarlo MilandriStefano VecchiaFabio GelsominoDavide TassinariStefano TamberiIlaria BernardiniCaterina AccetturaGiovanni Luca FrassinetiDino AmadoriOriana NanniPublished in: Therapeutic advances in medical oncology (2020)
Our results seem to suggest that B confers a PFS advantage when administered in combination with second-line chemotherapy, which could help to improve current international guidelines on optimal sequential treatment strategies.